3274 related articles for article (PubMed ID: 7600560)
1. The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.
Palomares T; Bilbao P; Alonso-Varona A; Barberá-Guillem E
Cancer Immunol Immunother; 1995 May; 40(5):292-8. PubMed ID: 7600560
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells.
Palomares T; Alonso-Varona A; Alvarez A; Castro B; Calle Y; Bilbao P
Clin Exp Metastasis; 1997 May; 15(3):329-37. PubMed ID: 9174132
[TBL] [Abstract][Full Text] [Related]
3. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
4. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
5. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
6. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma.
Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
J Exp Ther Oncol; 2003; 3(4):161-8. PubMed ID: 14567287
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
8. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
9. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK.
Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y
Oncology; 1994; 51(3):296-302. PubMed ID: 8196915
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
11. L-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases.
Bilbao P; del Olmo M; Alonso-Varona A; Castro B; Bilbao J; Palomares T
Melanoma Res; 2002 Feb; 12(1):17-26. PubMed ID: 11828254
[TBL] [Abstract][Full Text] [Related]
12. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
13. Immune regulation of metastasis from in vivo derived syngeneic murine melanoma.
Harning R; Koo GC; Szalay J
Reg Immunol; 1990; 3(2):97-102. PubMed ID: 1965137
[TBL] [Abstract][Full Text] [Related]
14. Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.
del Olmo M; Alonso-Varona A; Castro B; Calle Y; Bilbao P; Palomares T
Melanoma Res; 2000 Apr; 10(2):103-12. PubMed ID: 10803710
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
[TBL] [Abstract][Full Text] [Related]
16. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
18. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.
Goldfarb RH; Ohashi M; Brunson KW; Kirii Y; Kotera Y; Basse PH; Kitson RP
Anticancer Res; 1998; 18(3A):1441-6. PubMed ID: 9673353
[TBL] [Abstract][Full Text] [Related]
20. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1995 May; 59(1):35-9. PubMed ID: 7745975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]